Clinical trial · Observational
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
NCT03053999CI-TRIAL-00040561unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to identify predictors of disease in patients with hyperparathyroidism (HPTH) who undergo surgery.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperparathyroidism | — | UNRESOLVED | — |
| Multiple Endocrine Neoplasia | Multiple Endocrine Neoplasia | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data Review | Other | — | UNRESOLVED |
| Genome Sequencing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Parathyroidectomy Tissue and Data
- description
- Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors. Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
- interventionNames
- Other: Genome Sequencing
- Other: Data Review
Primary outcomes (1)
- measure
- Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Genome Sequencing
- timeFrame
- 10 years
Secondary outcomes (1)
- measure
- Identification of Somatic Mutations and Inherited Genetic Variants to Help Predict the Development of Pancreatic Neuroendocrine Tumors (PNET) in Participants with Hyperparathyroidism by Data Review
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. MEN1 patients who have undergone parathyroidectomy and did not develop PNET. 2. MEN1 patients who have undergone parathyroidectomy and had surgical removal of PNET. Exclusion Criteria: N/A
References
Publications (0)
Data not yet available
No reference posted for this study.